

I hereby certify that this communication is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 26, 1993

FELPE & LYNCH

LUD 253.3-JEL/NDH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thierry Boon et al.  
Serial No. : 07/807,043  
Filed : December 12, 1991  
For : THE NUCLENTIDE SEQUENCE ENCODING THE  
TUMOR REJECTION ANTIGEN PRECURSOR, MAGE-  
1 (AS AMENDED)  
Group Art Unit : 1813  
Examiner : J. Ellis

Attention: Office of Publications  
Allowed Applications Batch No. L60

March 26, 1993

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. § 1.312(a)

S I R:

Applicants acknowledge with appreciation the Notice of Allowance dated March 19, 1993. Upon review, it appears that claim 23 should not depend from claim 1, in view of the amendments made to each. As such, this amendment seeks to change claim 23 to dependent form. Further, claims paralleling claim 42, but depending upon claims 147 and 148 are believed proper.

No fees are believe due with this amendment. Should fees be required, however, it is asked that they be charged to Deposit Account 06-0530.

Please amend this application as follows:

8